Ocugen: Maintaining 'Buy' Rating On Positive OCU410ST Regulatory Developments

Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The ...

FDA misses another deadline on proposed ban on formaldehyde in hair-straightening products

The US Food and Drug Administration has missed its latest deadline to propose banning formaldehyde and certain formaldehyde-releasing chemicals from hair-straightening products, often used by Black ...
Ophthalmology Times

FDA Clears IND application for GenEditBio’s GEB-101 in TGFBI corneal dystrophy

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...